Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC

Lv, Fengxiang; Lu, Minmin; Cheung, Kenneth M.C.; Leung, Victor; Zhou, Guangqian

doi:10.2174/157488812804484611

Cited by 45 publications

(43 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, only a fraction of CFU‐Fs from plastic adherence isolated MSCs (PA‐MSCs) exhibited multipotency , indicating that PA‐MSCs comprised a heterogeneous population of cells with different lineage commitment , which may relate to their in vivo environment. This is reflected in the differences in the protein expression profile, cytokine profile, or differentiation potency of various sources of MSCs (reviewed in ). For example, the percentage of BM CFU‐Fs with osteogenic potency was higher than that with adipogenic potency .…”

Section: Introductionmentioning

confidence: 99%

Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells

et al. 2014

View full text Add to dashboard Cite

The concept of mesenchymal stem cells (MSCs) is becoming increasingly obscure due to the recent findings of heterogeneous populations with different levels of stemness within MSCs isolated by traditional plastic adherence. MSCs were originally identified in bone marrow and later detected in many other tissues. Currently, no cloning based on single surface marker is capable of isolating cells that satisfy the minimal criteria of MSCs from various tissue environments. Markers that associate with the stemness of MSCs await to be elucidated. A number of candidate MSC surface markers or markers possibly related to their stemness have been brought forward so far, including Stro-1, SSEA-4, CD271, and CD146, yet there is a large difference in their expression in various sources of MSCs. The exact identity of MSCs in vivo is not yet clear, although reports have suggested they may have a fibroblastic or pericytic origin. In this review, we revisit the reported expression of surface molecules in MSCs from various sources, aiming to assess their potential as MSC markers and define the critical panel for future investigation. We also discuss the relationship of MSCs to fibroblasts and pericytes in an attempt to shed light on their identity in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…During the past several decades, MSCs have been successfully harvested from various tissues, such as bone marrow (BM), umbilical cord blood (UCB), umbilical cord (UC) tissue and adipose tissue (AT) [5][6][7][8][9]. However, loss of potency (proliferation and differentiation capability), limitations with respect to the availability of autologous cells (aging and agerelated disorders), and the invasiveness of the procedures used for cell extraction have severely hampered the use of BM-, UCB-, UC-and AT-derived MSCs in clinical applications [10,11].…”

Section: Introductionmentioning

confidence: 99%

Extracellular Vesicles Secreted by Human Urine-Derived Stem Cells Promote Ischemia Repair in a Mouse Model of Hind-Limb Ischemia

Zhu

Niu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Our previous studies have shown that human urine-derived stem cells (USCs) have great potential as a cell source for cytotherapy and tissue engineering and that extracellular vesicles (EVs) secreted by USCs (USCs-EVs) can prevent diabetes-induced kidney injury in an animal model. The present study was designed to evaluate the effects of USCs-EVs on ischemia repair. Methods: USCs-EVs were isolated and purified by a battery of centrifugation and filtration steps. The USCs-EVs were then characterized by transmission electron microscopy, western blot and tunable resistive pulse sensing techniques. After intramuscularly transplanting USCs-EVs into an ischemic mouse hind-limb, we observed the therapeutic effects of USCs-EVs on perfusion by laser doppler perfusion imaging, angiogenesis and muscle regeneration by histology and immunohistochemistry techniques over 21 days. We subsequently tested whether USCs-EVs can induce the proliferation of a human microvascular endothelial cell line HMEC-1 and a mouse myoblast cell line C2C12 by cell counting kit 8 assay in vitro. Meanwhile, the potential growth factors in the USCs-EVs and supernatants of the USCs cultures were detected by enzyme-linked immunosorbent assay. Results: The USCs-EVs were spherical vesicles with a diameter of 30–150 nm and expressed exosomal markers, such as CD9, CD63 and Tsg101. Ischemic limb perfusion and function were markedly increased in the hind-limb ischemia (HLI) model after USCs-EVs administration. Moreover, angiogenesis and muscle regeneration levels were significantly higher in the USCs-EVs treatment group than in the PBS group. The in vitro experiments showed that USCs-EVs facilitated HMEC-1 and C2C12 cell proliferation in a dose-dependent manner. Conclusions: These results revealed for the first time that USCs-EVs efficiently attenuate severe hind-limb ischemic injury and represent a novel therapy for HLI.

show abstract

“…Currently, the study on the utilization of MSCs in disc repair mostly focus on bone marrow derived MSCs. Nevertheless, MSCs can be isolated from many organs and tissues with distinct differences in characteristics and differentiation potential (reviewed in (86)). Bone marrow derived MSCs may not be the most superior source due to its high spontaneous osteogenic tendency (87).…”

Section: Discussionmentioning

confidence: 99%

Cell-Based Therapies for Degenerative Disc Diseases

Leung

Cheung

2016

Operative Techniques in Orthopaedics

View full text Add to dashboard Cite

Intervertebral discs (IVDs) degeneration are responsible for the majority of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases (DDD) involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein/growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provides the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source include chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells and mesenchymal stem cells (MSCs). Results of several clinical trials suggest that MSCs is the best choice of cell source for IVD regeneration. The remaining concern is that the harsh environment of the degenerated disc may have impact on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require a earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome.

show abstract

Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC

Cited by 45 publications

References 94 publications

Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells

Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells

Extracellular Vesicles Secreted by Human Urine-Derived Stem Cells Promote Ischemia Repair in a Mouse Model of Hind-Limb Ischemia

Cell-Based Therapies for Degenerative Disc Diseases

Contact Info

Product

Resources

About